ADP-TILIL7

Phase 1Biologic

IInge Marie Svane

ADP-TILIL7 is one of 49 biologic programs targeting Metastatic Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Metastatic Melanoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

23 2

DTIC-Dome

Bayer

Phase 3

17 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

46 4

Mektovi

Pfizer

Phase 3

7 5

Taxol

Teva

Phase 3

7 6

Braftovi

Pfizer

Phase 3

6 7

Cotellic

Roche

Phase 3

6 8

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

17 9

Fabhalta

Regeneron

Phase 3

1 10

Libtayo

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Metastatic Melanoma

NCT06204991

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

Recruiting·IInge Marie Svane·Phase 1·NCT06204991·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADP-TILIL7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADP-TILIL7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADP-TILIL7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inge Marie Svane company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IInge Marie Svane

ADP-TILIL7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News